- Home
- CLRB
as 12-18-2024 11:34am EST
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 10.7M | IPO Year: | N/A |
| Target Price: | $28.00 | AVG Volume (30 days): | 3.8M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.23 - $4.45 | Next Earning Date: | 11-18-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cellectar Biosciences Inc. News
CLRB Breaking Stock News: Dive into CLRB Ticker-Specific Updates for Smart Investing
Benzinga
7 days ago
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
GlobeNewswire
8 days ago
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
MT Newswires
a month ago
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $14, Maintains Outperform Rating
Thomson Reuters StreetEvents
a month ago
Q3 2024 Cellectar Biosciences Inc Earnings Call
GlobeNewswire
a month ago
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
GlobeNewswire
a month ago
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
GlobeNewswire
a month ago
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
GlobeNewswire
a month ago
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024
Compare CLRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLRB Cellectar Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.